HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells.
HRF20, a 20 kDa homologous restriction factor, is a membrane glycoprotein anchored via galactosyl phosphatidyl inositol. Its function is to protect cells from attack by homologous complement. Adsorption of purified HRF20 to Raji cells which have little, if any, of this factor increased their resistance to cytolysis by homologous complement. However, the same cells treated with HRF20 remained sensitive to cytotoxic attack by IL-2 activated lymphocytes (lymphokine activated killer cells; LAK cells). Since LAK cells are effector cells which release perforin, HRF20 does not appear to protect cells from the damage caused by perforin.
Okada
H
H
Department of Molecular Biology, Nagoya City University School of Medicine, Japan.
Okada
N
N
Hideshima
T
T
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000276:immunology / Q000494:pharmacology*; D002051:Burkitt Lymphoma; D018957:CD59 Antigens; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000276:immunology / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D018957:CD59 Antigens; D008562:Membrane Glycoproteins